BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30739715)

  • 1. MpMRI of the prostate: is there a role for semi-quantitative analysis of DCE-MRI and late gadolinium enhancement in the characterisation of prostate cancer?
    Cristel G; Esposito A; Briganti A; Damascelli A; Brembilla G; Freschi M; Ambrosi A; Montorsi F; Del Maschio A; De Cobelli F
    Clin Radiol; 2019 Apr; 74(4):259-267. PubMed ID: 30739715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
    Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
    World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of gadolinium in magnetic resonance imaging for early prostate cancer diagnosis: A diagnostic accuracy study.
    Cosma I; Tennstedt-Schenk C; Winzler S; Psychogios MN; Pfeil A; Teichgraeber U; Malich A; Papageorgiou I
    PLoS One; 2019; 14(12):e0227031. PubMed ID: 31869380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Temporal Resolution on Diagnostic Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate.
    Othman AE; Falkner F; Weiss J; Kruck S; Grimm R; Martirosian P; Nikolaou K; Notohamiprodjo M
    Invest Radiol; 2016 May; 51(5):290-6. PubMed ID: 26619282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization.
    Cristel G; Esposito A; Damascelli A; Briganti A; Ambrosi A; Brembilla G; Brunetti L; Antunes S; Freschi M; Montorsi F; Del Maschio A; De Cobelli F
    Eur J Radiol; 2019 Sep; 118():51-57. PubMed ID: 31439258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
    Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
    Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI).
    Gatti M; Faletti R; Calleris G; Giglio J; Berzovini C; Gentile F; Marra G; Misischi F; Molinaro L; Bergamasco L; Gontero P; Papotti M; Fonio P
    Abdom Radiol (NY); 2019 May; 44(5):1883-1893. PubMed ID: 30788558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice.
    Zawaideh JP; Sala E; Shaida N; Koo B; Warren AY; Carmisciano L; Saeb-Parsy K; Gnanapragasam VJ; Kastner C; Barrett T
    Eur Radiol; 2020 Jul; 30(7):4039-4049. PubMed ID: 32166495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Evaluation of late Gadolinium Enhancement to the Differential Diagnosis of Prostate Cancer and Prostatitis in mpMRI.
    Aydin H; Topsakal K; Ayyildiz VA; Aydin H; Karaibrahimoglu A
    J Coll Physicians Surg Pak; 2023 Jan; 33(1):20-26. PubMed ID: 36597230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Added value of diffusion-weighted images and dynamic contrast enhancement in multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer in the PICTURE trial.
    Eldred-Evans D; Neves JB; Simmons LAM; Kanthabalan A; McCartan N; Shah TT; Arya M; Charman SC; Freeman A; Moore CM; Punwani S; Emberton M; Ahmed HU
    BJU Int; 2020 Mar; 125(3):391-398. PubMed ID: 31733173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
    Ziayee F; Ullrich T; Blondin D; Irmer H; Arsov C; Antoch G; Quentin M; Schimmöller L
    PLoS One; 2021; 16(4):e0249532. PubMed ID: 33819295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of double inversion recovery magnetic resonance imaging (DIR-MRI) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in detection of prostate cancer: A pilot study.
    Onwuharine EN; Clark AJ
    Radiography (Lond); 2020 Aug; 26(3):234-239. PubMed ID: 32052752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework.
    Reynolds HM; Williams S; Jackson P; Mitchell C; Hofman MS; Hicks RJ; Murphy DG; Haworth A
    BJU Int; 2019 Jun; 123(6):1020-1030. PubMed ID: 30536698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central zone lesions on magnetic resonance imaging: Should we be concerned?
    Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
    Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Often is the Dynamic Contrast Enhanced Score Needed in PI-RADS Version 2?
    Roh AT; Fan RE; Sonn GA; Vasanawala SS; Ghanouni P; Loening AM
    Curr Probl Diagn Radiol; 2020; 49(3):173-176. PubMed ID: 31126664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study.
    Bosaily AE; Frangou E; Ahmed HU; Emberton M; Punwani S; Kaplan R; Brown LC; Freeman A; Jameson C; Hindley R; Peppercorn D; Thrower A; Winkler M; Barwick T; Stewart V; Burns-Cox N; Burn P; Ghei M; Kumaradevan J; Prasad R; Ash-Miles J; Shergill I; Agarwal S; Rosario D; Salim F; Bott S; Evans H; Henderson A; Ghosh S; Dudderidge T; Smart J; Tung K; Kirkham A;
    Eur Urol; 2020 Oct; 78(4):503-511. PubMed ID: 32312543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Using Low-Dose Gadolinium: Comparative Performance With Standard Dose in Prostate Cancer Diagnosis.
    He D; Chatterjee A; Fan X; Wang S; Eggener S; Yousuf A; Antic T; Oto A; Karczmar GS
    Invest Radiol; 2018 Oct; 53(10):609-615. PubMed ID: 29702525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study.
    Choi MH; Kim CK; Lee YJ; Jung SE
    AJR Am J Roentgenol; 2019 Apr; 212(4):839-846. PubMed ID: 30779662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media?
    Huebner NA; Korn S; Resch I; Grubmüller B; Gross T; Gale R; Kramer G; Poetsch N; Clauser P; Haitel A; Fajkovic H; Shariat SF; Baltzer PA
    Eur Radiol; 2021 Jun; 31(6):3754-3764. PubMed ID: 33263793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.